AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22824238 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (≥1 pack-year) in RA patients on MTX
Number of subjects: 505
Study 22824238 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (current smokers)
Number of subjects: 505
Study 22824238 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (low to moderate)
Number of subjects: 505
Study 22824238 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (control group)
Number of subjects: 505
Study 22824434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent rhythm monitoring (IRM)
Number of subjects: 647
Study 22824434 — intervention group
Group type: COMPARATOR
Intervention: Continuous monitoring (CM)
Number of subjects: 647
Study 22824446 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a recently released male partner
Number of subjects: 653
Study 22824929 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3-4 mg/kg/hr
Number of subjects: 13
Study 22824929 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.8%
Number of subjects: 13
Study 22824929 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3-4 mg/kg/hr (after isoflurane)
Number of subjects: 13
Study 22824936 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing cumulative fluid balance (mL/kg) on day 3
Number of subjects: 168
Study 22824936 — intervention group
Group type: COMPARATOR
Intervention: Daily fluid balance on days 1-3 and cumulative fluid balance on days 1-7
Number of subjects: 168
Study 22825216 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor (TKI) therapy targeting BCR-ABL1
Number of subjects: 0
Study 22825216 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous inhibition of BCR-ABL1 and other newly identified targets
Number of subjects: 0
Study 22825536 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation drug-eluting stents (DES)
Number of subjects: 180
Study 22825536 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 180
Study 22826079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosensory deactivation (by breathing 100% oxygen)
Number of subjects: 18
Study 22826079 — intervention group
Group type: COMPARATOR
Intervention: Deep breathing test
Number of subjects: 18
Study 22826079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoreceptor deactivation
Number of subjects: 18
Study 22826359 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel added to aspirin
Number of subjects: 90934
Study 22827969 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal intention not to breastfeed
Number of subjects: 999
Study 22827969 — intervention group
Group type: EXPERIMENTAL
Intervention: Being undecided about how to feed
Number of subjects: 999
Study 22827969 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported breast health problems
Number of subjects: 999
Study 22827969 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother having her own income
Number of subjects: 999
Study 22827969 — intervention group
Group type: COMPARATOR
Intervention: HIV status (HIV-negative vs HIV-positive)
Number of subjects: 999
Study 22828177 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based coaching intervention (HOPE), 10 sessions over 12 weeks
Number of subjects: 8
Study 22828668 — intervention group
Group type: EXPERIMENTAL
Intervention: Exaggerated BP response during training
Number of subjects: 44
Study 22828668 — intervention group
Group type: COMPARATOR
Intervention: Normal BP response during training
Number of subjects: 44
Study 22828668 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h ambulatory blood pressure monitoring during training
Number of subjects: 44
Study 22828668 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting period for athletes with exaggerated BP response
Number of subjects: 44
Study 22829110 — intervention group
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA) for 2 days, followed by theophylline and valproic acid
Number of subjects: 24
Study 22829110 — intervention group
Group type: COMPARATOR
Intervention: none
Number of subjects: 24
Study 22829629 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell-depleted marrow mononuclear cell boost (> 99.99% NABMC)
Number of subjects: 0
Study 22829629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo-expanded mesenchymal stromal cells (MSCs)
Number of subjects: 0
Study 22829629 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-(plastic)-adherent bone marrow cells (NABMCs)
Number of subjects: 0
Study 22829920 — intervention group
Group type: EXPERIMENTAL
Intervention: First line ART
Number of subjects: 49
Study 22829920 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infection
Number of subjects: 49
Study 22829920 — intervention group
Group type: COMPARATOR
Intervention: Control (seronegative subjects)
Number of subjects: 49
Study 22829920 — intervention group
Group type: EXPERIMENTAL
Intervention: Three ART regimens
Number of subjects: 49
Study 22829927 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects developing HAPE
Number of subjects: 18
Study 22829927 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 18
Study 22830581 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 concentrations in patients who failed to achieve goals for central venous pressure (CVP)
Number of subjects: 30
Study 22830581 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 concentrations in patients who failed to achieve goals for pulmonary capillary wedge pressure (PCWP)
Number of subjects: 30
Study 22830581 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 concentrations associated with adverse events
Number of subjects: 30
Study 22830581 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated sST2 during the first 48 hours following ICU admission
Number of subjects: 30
Study 22831708 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5 mg once daily, up-titrated to a maximum of 20 mg/day)
Number of subjects: 126
Study 22833362 — intervention group
Group type: EXPERIMENTAL
Intervention: Rontalizumab (0.3 to 10 mg/kg, IV or subcutaneous)
Number of subjects: 0
Study 22833362 — intervention group
Group type: EXPERIMENTAL
Intervention: Rontalizumab (3 mg/kg and 10 mg/kg IV)
Number of subjects: 0
Study 22833362 — intervention group
Group type: EXPERIMENTAL
Intervention: Rontalizumab
Number of subjects: 0
Study 22833546 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib 20 mg/m² intravenously twice weekly for 3 of 4 weeks in cycle 1, then 27 mg/m² for ≤ 12 cycles
Number of subjects: 266
Study 22833546 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Number of subjects: 266
Study 22835045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 1500 mg/m(2), vincristine, rituximab, prednisone, methotrexate 3 g/m(2), and intrathecal cytarabine for 2 cycles, followed by high-dose cyclophosphamide (50 mg/kg/day for 4 days) and rituximab.
Number of subjects: 21
Study 22835762 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurant Stent Graft
Number of subjects: 1262
Study 22836031 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk from obese mothers
Number of subjects: 18
Study 22836031 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk samples from elective cesarean delivery mothers
Number of subjects: 18
Study 22836031 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum samples
Number of subjects: 18
Study 22836031 — intervention group
Group type: EXPERIMENTAL
Intervention: 1- and 6-mo milk samples
Number of subjects: 18
Study 22837004 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (VOR); single dose administered to patients
Number of subjects: 8
Study 22837373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg b.i.d.) plus standard-dose clopidogrel (75 mg/d)
Number of subjects: 80
Study 22837373 — intervention group
Group type: COMPARATOR
Intervention: Double-dose clopidogrel (150 mg/d)
Number of subjects: 80
Study 22837378 — intervention group
Group type: EXPERIMENTAL
Intervention: CHRNA5/3 region genetic risk factor for airflow obstruction in ever smokers
Number of subjects: 3368
Study 22837378 — intervention group
Group type: EXPERIMENTAL
Intervention: HTR4 gene association
Number of subjects: 3368
Study 22837378 — intervention group
Group type: COMPARATOR
Intervention: Top single-nucleotide polymorphisms in ADAM19, RARB, PPAP2B, and ADAMTS19
Number of subjects: 3368
Study 22837492 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV and AIDSVAX B/E vaccine
Number of subjects: 114
Study 22837492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 22838970 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 1146
Study 22838970 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1146
Study 22838970 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones and oral combination drugs
Number of subjects: 1146
Study 22838970 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 1146
Study 22838970 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1146
Study 22839200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine (capecitabine 2000 mg/m² daily in two divided doses, days 1-14, every 21 days; lapatinib 1250 mg once daily)
Number of subjects: 186
Study 22839200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 186
Study 22839417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) assessment of left ventricular (LV) mass and volume
Number of subjects: 91
Study 22839417 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of LV mass index
Number of subjects: 91
Study 22839417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of LV adaptation
Number of subjects: 91
Study 22839417 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of asymmetric patterns of wall thickening
Number of subjects: 91
Study 22839504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous endotoxin (LPS) injection
Number of subjects: 14
Study 22839504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 14
Study 22839656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (target temperature 35°C within 1.5 hours after surgery, maintained at 33°C for 48 hours)
Number of subjects: 489
Study 22839656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (target temperature 35°C within 1.5 hours after surgery)
Number of subjects: 489
Study 22839656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (target temperature more than 1.5 hours after surgery)
Number of subjects: 489
Study 22839656 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 489
Study 22840315 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 (liposome-encapsulated cytarabine:daunorubicin at a 5:1 molar ratio)
Number of subjects: 48
Study 22840315 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 48
Study 22840761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (.5 mg/kg) administered open-label three times weekly over a 12-day period
Number of subjects: 24
Study 22842561 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care
Number of subjects: 360
Study 22842561 — intervention group
Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 360
Study 22842843 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble receptor activator of nuclear factor-κB ligand in HIV-infected individuals
Number of subjects: 78
Study 22842843 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary segments with plaque in HIV-infected individuals
Number of subjects: 78
Study 22842843 — intervention group
Group type: EXPERIMENTAL
Intervention: Agatston calcium score in HIV-infected individuals
Number of subjects: 78
Study 22843211 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8055 10 mg
Number of subjects: 17
Study 22843211 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8055 40 mg
Number of subjects: 17
Study 22843211 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8055 60 mg
Number of subjects: 17
Study 22843211 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8055 90 mg
Number of subjects: 17
Study 22843787 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure RCM
Number of subjects: 3375
Study 22843787 — intervention group
Group type: EXPERIMENTAL
Intervention: RCM/HCM phenotype
Number of subjects: 3375
Study 22843787 — intervention group
Group type: COMPARATOR
Intervention: Heart failure
Number of subjects: 3375
Study 22843787 — intervention group
Group type: COMPARATOR
Intervention: Lower fractional shortening z score
Number of subjects: 3375
Study 22843787 — intervention group
Group type: COMPARATOR
Intervention: Higher posterior wall thickness (RCM/HCM group only)
Number of subjects: 3375
Study 22845802 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 22845802 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-smokers or non-clopidogrel users)
Number of subjects: 0
Study 22847303 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) with partial T cell depletion (TCD) and preemptive donor lymphocyte infusion (DLI).
Number of subjects: 38
Study 22847303 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusion (DLI) for residual disease.
Number of subjects: 38
Study 22848378 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted pandemic vaccine (Pandemrix®)
Number of subjects: 406
Study 22848407 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressive disorder (MDD)
Number of subjects: 136
Study 22848407 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 136
Study 22848542 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 3 weeks in-hospital and 15 weeks at home
Number of subjects: 35
Study 22848542 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 35
Study 22848772 — intervention group
Group type: EXPERIMENTAL
Intervention: rBS-WC oral cholera vaccine (at least one dose)
Number of subjects: 13736
Study 22848772 — intervention group
Group type: COMPARATOR
Intervention: Not vaccinated (control group)
Number of subjects: 13736
Study 22848877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge preservation procedures (RPP) with bioactive glass (Inion BioRestore, Inion Oy)
Number of subjects: 13
Study 22849707 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) of 5 cm H₂O during a 30-minute spontaneous breathing trial
Number of subjects: 52
Study 22849707 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who passed the spontaneous breathing trial but then failed extubation)
Number of subjects: 52
Study 22850119 — intervention group
Group type: COMPARATOR
Intervention: HPV-16/18 vaccine trial control group
Number of subjects: 2017
Study 22850119 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who reported anal intercourse
Number of subjects: 2017
Study 22850119 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who reported no anal intercourse
Number of subjects: 2017
Study 22851612 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal cognitive assessment (MoCA)
Number of subjects: 90
Study 22851612 — intervention group
Group type: COMPARATOR
Intervention: mini-mental state examination (MMSE)
Number of subjects: 90
Study 22851612 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cerebral infarction
Number of subjects: 90
Study 22853723 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop inpatient sessions (MD-Logic Artificial Pancreas)
Number of subjects: 7
Study 22853723 — intervention group
Group type: COMPARATOR
Intervention: Homecare open-loop system
Number of subjects: 7
Study 22853816 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony stimulating factor (GM-CSF) added to alemtuzumab and rituximab regimen
Number of subjects: 33
Study 22853816 — intervention group
Group type: COMPARATOR
Intervention: Alemtuzumab and rituximab regimen without GM-CSF (historical control)
Number of subjects: 33
Study 22854002 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-assisted subcutaneous infusion (EASI) using human recombinant hyaluronidase (HRH)
Number of subjects: 18
Study 22854293 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication sharing
Number of subjects: 315
Study 22854293 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of non-prescribed medications
Number of subjects: 315
Study 22854293 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 315
Study 22854293 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial hardship
Number of subjects: 315
Study 22854293 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent use of heroin
Number of subjects: 315
Study 22854293 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent use of cocaine
Number of subjects: 315
Study 22854661 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 µg HA AS03-adjuvanted H1N1 2009 vaccine
Number of subjects: 50
Study 22855388 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MCV4) in the prior-MPSV4 group (n = 153)
Number of subjects: 238
Study 22855388 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MCV4) in the meningococcal vaccine-naïve group (n = 85)
Number of subjects: 238
Study 22855388 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of MCV4 in both groups
Number of subjects: 238
Study 22855732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 607
Study 22855732 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 607
Study 22856551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified LDL-C lowering therapy (various regimens including simvastatin/ezetimibe fixed-dose combination, add-on ezetimibe, and statin therapy at maintained or increased doses)
Number of subjects: 1682
Study 22856636 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor (C1-INH) concentrate at a dosage of 20 U/kg
Number of subjects: 18
Study 22856636 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor (C1-INH) concentrate
Number of subjects: 18
Study 22856635 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor (C1 INH-nf); 1000 U administered i.v. within 24 hours before procedures
Number of subjects: 41
Study 22856635 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor (C1 INH-nf)
Number of subjects: 41
Study 22858270 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared cerebral oximeter
Number of subjects: 100
Study 22858270 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration phase (Phase I)
Number of subjects: 100
Study 22858270 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation phase (Phase II)
Number of subjects: 100
Study 22858384 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation testing (DT+)
Number of subjects: 2120
Study 22858384 — intervention group
Group type: COMPARATOR
Intervention: No defibrillation testing (DT-)
Number of subjects: 2120
Study 22858384 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 2120
Study 22858800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncoplastic surgery (OS)
Number of subjects: 50
Study 22858800 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NC)
Number of subjects: 50
Study 22859235 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-690,050 (tasocitinib) at doses greater than 5 mg
Number of subjects: 0
Study 22859235 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-690,050 at 2, 5, and 15 mg twice daily
Number of subjects: 0
Study 22859235 — intervention group
Group type: COMPARATOR
Intervention: INCB018424 (ruxolitinib) used topically at 0.5%, 1%, 1.5%
Number of subjects: 0
Study 22859259 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 286
Study 22859259 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy-directed surveillance strategy
Number of subjects: 286
Study 22859609 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 IU/kg rIX-FP
Number of subjects: 25
Study 22859609 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU/kg rIX-FP
Number of subjects: 25
Study 22859609 — intervention group
Group type: EXPERIMENTAL
Intervention: rIX-FP
Number of subjects: 25
Study 22860080 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC-containing-HAART
Number of subjects: 30
Study 22862954 — intervention group
Group type: EXPERIMENTAL
Intervention: DPX-0907
Number of subjects: 23
Study 22863201 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids (AA) and branched-chain amino acids (BCAA)
Number of subjects: 0
Study 22863201 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 22863355 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended duration thromboprophylaxis
Number of subjects: 0
Study 22863355 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy and/or placebo
Number of subjects: 0
Study 22863892 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival plaque samples from diseased sites (DD)
Number of subjects: 51
Study 22863892 — intervention group
Group type: COMPARATOR
Intervention: Subgingival plaque samples from healthy sites (HS and HC)
Number of subjects: 51
Study 22863892 — intervention group
Group type: COMPARATOR
Intervention: Subgingival plaque samples from healthy children
Number of subjects: 51
Study 22865900 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate ovarian stimulation
Number of subjects: 185
Study 22865900 — intervention group
Group type: COMPARATOR
Intervention: Unstimulated cycle
Number of subjects: 185
Study 22865914 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-specific CD4+ T lymphocytes during primary CMV infection
Number of subjects: 0
Study 22865914 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed death-1 inhibition
Number of subjects: 0
Study 22867706 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel releasing balloon (DCB)
Number of subjects: 81
Study 22868877 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment with amisulpride for 6 weeks
Number of subjects: 23